The Effect of a Novel Antibody-based Drug, Prospekta, on Brain Electrical Activity in Mice

An affinity-purified antibody to the calcium-binding protein S100B that has undergone gradual technological processing and was additionally modified with an electromagnetic signal is an active pharmaceutical ingredient of the novel neurotropic drug Prospekta. Earlier studies have shown that the drug possesses a wide range of S100B-mediated pharmacological effects. Here, we investigated Prospekta's impact on baseline brain electrical activity to deepen understanding of its mechanism of action.

Extradural electrodes were surgically implanted into the skulls of adult male socially submissive mice. Animals were orally administered Prospekta for 5 days starting from the end of the recovery period. Brain baseline activity was recorded for 5 minutes after placing the mice in the arena. EEG band power (1-130 Hz, delta to high-gamma) was then analyzed quantitatively.

Prospekta administration reduced theta and alpha band power in the left prefrontal cortex. Additionally, the drug showed a trend toward altering electrical activity coherence between the left prefrontal cortex and the right hippocampus, manifesting as a subtle, visually present phase shift across the examined brain regions.

In a model recapitulating human cognitive and emotional impairments, Prospektainduced EEG alterations indicate a translational mechanism of neural modulation that may underlie behavioral effects, highlighting the need for future studies connecting these changes with functional outcomes.

Our findings suggest that Prospekta modulates S100B-dependent processes, as evidenced by altered EEG oscillatory power and coherence. These effects may underlie the drug's influence on cognitive and behavioral regulation.